News

Approved under the tradename Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The FDA approval is

The trial follows two months of effort by a consortium led by the World Health Organisation (WHO) to bring this vaccine into clinical studies in West Africa. The

ISIS-TTR is an antisense drug intends for the treatment of transthyretin amyloidosis, a genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. For the ISIS-TTR

Auxilium produces products in the men’s healthcare segment, and has expanded its product portfolio and pipeline to orthopedics, dermatology and other therapeutic areas. Auxilium Pharmaceuticals CEO and president

The eye drops progressively deliver the right amount of drug-infused nanoparticles to the surface of the eyeball over a period of five days before the body absorbs them.

Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using

Join Bürkert industry experts and Business Review Webinars, on 25 November to learn more about valuable insights to help your business. The first of a series of webinars

The death toll has reached 3,439 in the worst Ebola-hit nations Guinea, Liberia, and Sierra Leone. The two-year regional financial impact could reach around $32.6bn by the end

The latest deal follows similar third-party deal already established with Nitto Medic in Japan for the distribution of AdenoPlus. The company has also established similar deals in Switzerland,